Ergebnisse

Ergebnisse

Updates der neuen Ergebnisse

https://www.aerzteblatt.de/archiv/224889/Coronapandemie-Die-Rolle-epidemiologischer-Forschung-in-Gesundheitskrisen#literatur

https://www.aerzteblatt.de/archiv/221932/SARS-CoV-2-Seropraevalenz-in-Deutschland

2. Rodiah, I., Vanella, P., Kuhlmann, A., Jaeger, V. K., Harries, M., Krause, G., . . . Lange, B. (2021). Age-specific Contribution of Contacts to Transmission of SARS-CoV-2 in Germany. medRxiv

3. Dulovic, A., Kessel, B., Harries, M., Becker, M., Ortmann, J., Griesbaum, J., … & Strengert, M. (2022). Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in immunology, 13.

4. Junker, D., Becker, M., Wagner, T. R., Kaiser, P. D., Maier, S., Grimm, T. M., . . . Schneiderhan-Marra, N. (2022). Antibody binding and ACE2 binding inhibition is significantly reduced for both the BA1 and BA2 omicron variants. Clinical Infectious Diseases.

5. Beermann, S., Dörr, M., Grill, E., Karch, A., Lange, B., & Zeeb, H. (2022). Coronapandemie: Die Rolle epidemiologischer Forschung in Gesundheitskrisen. Deutsches Ärzteblatt International, 119(17), A-753.

6.  Bridging the gap – estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel https://www.medrxiv.org/content/10.1101/2022.12.30.22284061v1

7. Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season – the IMMUNEBRIDGE project https://www.medrxiv.org/content/10.1101/2023.02.16.23285816v1

SARS-CoV-2-Seroprävalenz in Deutschland
Eine bevölkerungsbezogene sequenzielle Studie in sieben Regionen
SARS-CoV-2 seroprevalence in Germany—a population-based sequential study in seven regions
Dtsch Arztebl Int 2021; 118: 824-31; DOI: 10.3238/arztebl.m2021.0364